Cost effectiveness of urinary incontinence treatments
Three abstracts presented at the 48th Annual Meeting of the International Continence Society (ISC 2018), held in Philadelphia, USA on 28−31 August 2018, evaluated the cost effectiveness of treatment strategies for urinary incontinence.
Botox beats sacral neuromodulation
Sacral neuromodulation (SNM) delivered via the InterStim/Medtronic system appears to be more costly than botulinum toxin A (Botox; onabotulinumtoxinA) but similarly effective in women with refractory urgency urinary incontinence, according to findings of a US study.1
The multicentre Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment (ROSETTA) trial, conducted at nine US medical centres between February 2012 and July 2016, randomised 336 women with refractory urgency urinary incontinence (over six urgency urinary incontinence episodes [UUIEs] per day) to SNM or Botox. Patients with ≥50% reduction in UUIE after SNM were eligible for an implant. Patients randomised to Botox were allowed up...
- 1.Harvie H S, et al. Cost-Effectiveness of Sacral Neuromodulation vs. Botox for Refractory Urgency Urinary Incontinence: Results from the ROSETTA Trial. 48th Annual Meeting of the International Continence Society : abstr. 439, 28 Aug 2018. Available from: URL: https://www.ics.org/2018/abstract/439.
- 2.Jenks J, et al. The Clinical And Cost Effectiveness Of Acupuncture For Symptomatic IDO. 48th Annual Meeting of the International Continence Society : abstr. 676, 28 Aug 2018. Available from: URL: https://www.ics.org/2018/abstract/676.
- 3.Matta R, et al. Multi-channel urodynamic assessment in men with post-prostatectomy urinary incontinence: a cost utility analysis. 48th Annual Meeting of the International Continence Society : abstr. 248, 28 Aug 2018. Available from: URL: https://www.ics.org/2018/abstract/248.